Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial
Shun Lu,Wei Zhang,Lin Wu,Wenxiang Wang,Peng Zhang,Neotorch Investigators,Wentao Fang,Wenqun Xing,Qixun Chen,Lin Yang,Jiandong Mei,Lijie Tan,Xiaohong Sun,Shidong Xu,Xiaohua Hu,Guohua Yu,Dongliang Yu,Nong Yang,Yuping Chen,Jinlu Shan,Ligang Xing,Hui Tian,Xun Zhang,Ming Zhou,Haohui Fang,Guowu Wu,Yunpeng Liu,Minhua Ye,Lejie Cao,Jie Jiang,Xingya Li,Liangming Zhu,Danqing Li,Mingqiang Kang,Aihong Zhong,Keneng Chen,Nan Wu,Qian Sun,Haitao Ma,Kaican Cai,Changli Wang,Gen Lin,Kunshou Zhu,Yu Zhang,Xiaochun Zhang,Hong Hu,Wengang Zhang,Jun Chen,Zhixiong Yang,Xiaosheng Hang,Jian Hu,Yunchao Huang,Zhiye Zhang,Lumin Zhang,Liwei Zhang,Lunxu Liu,Dongmei Lin,Jie Zhang,Gang Chen,Yuan Li,Lei Zhu,Weihua Wang,Wenbo Yu,Dezhen Cao,Patricia Keegan,Sheng Yao
DOI: https://doi.org/10.1001/jama.2023.24735
IF: 11.816
2024-01-16
JAMA
Abstract:Importance: Adjuvant and neoadjuvant immunotherapy have improved clinical outcomes for patients with early-stage non-small cell lung cancer (NSCLC). However, the optimal combination of checkpoint inhibition with chemotherapy remains unknown. Objective: To determine whether toripalimab in combination with platinum-based chemotherapy will improve event-free survival and major pathological response in patients with stage II or III resectable NSCLC compared with chemotherapy alone. Design, setting, and participants: This randomized clinical trial enrolled patients with stage II or III resectable NSCLC (without EGFR or ALK alterations for nonsquamous NSCLC) from March 12, 2020, to June 19, 2023, at 50 participating hospitals in China. The data cutoff date for this interim analysis was November 30, 2022. Interventions: Patients were randomized in a 1:1 ratio to receive 240 mg of toripalimab or placebo once every 3 weeks combined with platinum-based chemotherapy for 3 cycles before surgery and 1 cycle after surgery, followed by toripalimab only (240 mg) or placebo once every 3 weeks for up to 13 cycles. Main outcomes and measures: The primary outcomes were event-free survival (assessed by the investigators) and the major pathological response rate (assessed by blinded, independent pathological review). The secondary outcomes included the pathological complete response rate (assessed by blinded, independent pathological review) and adverse events. Results: Of the 501 patients randomized, 404 had stage III NSCLC (202 in the toripalimab + chemotherapy group and 202 in the placebo + chemotherapy group) and 97 had stage II NSCLC and were excluded from this interim analysis. The median age was 62 years (IQR, 56-65 years), 92% of patients were male, and the median follow-up was 18.3 months (IQR, 12.7-22.5 months). For the primary outcome of event-free survival, the median length was not estimable (95% CI, 24.4 months-not estimable) in the toripalimab group compared with 15.1 months (95% CI, 10.6-21.9 months) in the placebo group (hazard ratio, 0.40 [95% CI, 0.28-0.57], P < .001). The major pathological response rate (another primary outcome) was 48.5% (95% CI, 41.4%-55.6%) in the toripalimab group compared with 8.4% (95% CI, 5.0%-13.1%) in the placebo group (between-group difference, 40.2% [95% CI, 32.2%-48.1%], P < .001). The pathological complete response rate (secondary outcome) was 24.8% (95% CI, 19.0%-31.3%) in the toripalimab group compared with 1.0% (95% CI, 0.1%-3.5%) in the placebo group (between-group difference, 23.7% [95% CI, 17.6%-29.8%]). The incidence of immune-related adverse events occurred more frequently in the toripalimab group. No unexpected treatment-related toxic effects were identified. The incidence of grade 3 or higher adverse events, fatal adverse events, and adverse events leading to discontinuation of treatment were comparable between the groups. Conclusions and relevance: The addition of toripalimab to perioperative chemotherapy led to a significant improvement in event-free survival for patients with resectable stage III NSCLC and this treatment strategy had a manageable safety profile. Trial registration: ClinicalTrials.gov Identifier: NCT04158440.